Other News

JanOne Announces Closing of $6.0 Million Common Stock Offering

Net proceeds will help support planning of clinical trials for JAN101, the company’s lead drug candidate LAS VEGAS, Feb. 2, 2021 /PRNewswire/ — JanOne Inc. (Nasdaq: JAN), a company focused on developing treatments for conditions that cause severe pain and drugs with non-addictive, pain-relieving properties, today announced the closing of previously announced its securities […]

Cardiovascular Systems, Inc. Announces Partnership With Chansu Vascular Techologies, LLC to Develop New Drug-Coated Balloon Technology

ST. PAUL, Minn.–(BUSINESS WIRE)–Cardiovascular Systems, Inc. (CSI®) (NASDAQ: CSII) announced today that it has partnered with Chansu Vascular Technologies, LLC (CVT) to develop novel peripheral and coronary everolimus drug-coated balloons (DCBs). This partnership brings together CSI’s leadership in the treatment of calcified arterial lesions with Dr. Philippe Marco, a pioneer […]

Neovasc Announces 2021 Renewal of German Reimbursement NUB Status 1 Designation for Neovasc Reducer for Treatment of Refractory Angina

VANCOUVER and MINNEAPOLIS, MN, Feb. 02, 2021 (GLOBE NEWSWIRE) — via NewMediaWire — Neovasc,  Inc. (“Neovasc” or the “Company”) (NASDAQ, TSX: NVCN) today announced that the German Institute for the Hospital Remuneration System(“InEK”) has awarded the Neovasc Reducer™ (“Reducer”), a CE-Marked medical device for the treatment of refractory angina, NUB Status 1 designation once […]

Cytokinetics Announces Recipients of Third Annual Communications Fellowship Grants

Total of $100,000 Awarded to Five Organizations to Support Communications and Community Outreach SOUTH SAN FRANCISCO, Calif., Feb. 02, 2021 (GLOBE NEWSWIRE) — Cytokinetics, Incorporated (Nasdaq: CYTK) today announced the recipients of its third annual Communications Fellowship Grant program, intended to support increased capacity in communications, awareness building and community engagement […]

BioCardia Update on Cell Therapy Product Development and 2021 Milestones

SAN CARLOS, Calif., Feb. 02, 2021 (GLOBE NEWSWIRE) — BioCardia®, Inc. [Nasdaq: BCDA] a leader in the development of comprehensive solutions for cardiovascular regenerative therapies, today provides an update on its cell therapy product development and 2021 milestones. BCDA-01, our CardiAMP autologous cell therapy under Phase III clinical development for the treatment of […]

First-of-its-Kind Randomized Clinical Trial Published in “The Lancet Infectious Diseases” Outlines Potential New Standard-Setting Best Practices for Peripheral IV Catheters

– There is robust evidence that the BD vascular care solution and skin antiseptic for peripheral intravenous catheters used in the CLEAN3 randomized clinical trial can help improve patient outcomes – Compared with standard approaches, the BD vascular care solution reduced the relative risk of catheter failure by 27%, resulting […]

PhysIQ Expands Clinical Leadership Team, Dr. Steve Steinhubl Joins as Chief Medical Officer

CHICAGO–(BUSINESS WIRE)–Dr. Steve Steinhubl, a leader in reinventing medicine through the convergence of healthcare and technology and an expert in physiology, has joined physIQ as Chief Medical Officer. Dr. Steinhubl will help advance the adoption of physIQ’s artificial intelligence (AI)-based analytics for improved clinical outcomes and lower costs. “Over the […]

AtriCure to Announce Fourth Quarter and Full Year 2020 Financial Results

MASON, Ohio–(BUSINESS WIRE)–AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced that it will release its fourth quarter and full year 2020 financial results on Tuesday, February 23, 2021. AtriCure will host a conference call at 4:30 p.m. Eastern […]

Edwards RESILIA Tissue Aortic Valve Demonstrates Favorable Safety and Efficacy at Five Years

AUSTIN, Texas, Jan. 31, 2021 /PRNewswire/ — Edwards Lifesciences (NYSE: EW) today announced new data from the COMMENCE clinical trial that demonstrate Edwards’ bioprosthetic surgical aortic valve with the company’s novel RESILIA tissue platform show favorable safety and hemodynamic performance through a median of five years follow-up. The data were presented at the […]

AngioDynamics Appoints Richard C. Rosenzweig Senior Vice President, General Counsel and Secretary, Promotes Juan Carlos Serna to Senior Vice President, Scientific & Clinical Affairs

LATHAM, N.Y.–(BUSINESS WIRE)–AngioDynamics, Inc. (NASDAQ: ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, peripheral vascular disease, and oncology, today announced that it has appointed Richard C. Rosenzweig as Senior Vice President, General Counsel, effective January 31, 2021. Mr. Rosenzweig will also serve as Corporate Secretary […]